Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Suzan Van Hoppe"'
Autor:
Findlay Bewicke-Copley, Koorosh Korfi, Shamzah Araf, Brendan Hodkinson, Emil Kumar, Thomas Cummin, Margaret Ashton-Key, Sharon Barrans, Suzan van Hoppe, Cathy Burton, Mohamed Elshiekh, Simon Rule, Nicola Crosbie, Andrew Clear, Maria Calaminici, Hendrik Runge, Robert K. Hills, David W. Scott, Lisa M. Rimsza, Geetha Menon, Chulin Sha, John R. Davies, Ai Nagano, Andrew Davies, Daniel Painter, Alexandra Smith, John Gribben, Kikkeri N. Naresh, David R. Westhead, Jessica Okosun, Andrew Steele, Daniel J. Hodson, Sriram Balasubramanian, Peter Johnson, Jun Wang, Jude Fitzgibbon
Publikováno v:
Blood Advances. 7:845-855
Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short
Autor:
Russell Patmore, Stuart E. Lacy, Philip A. Beer, Camilo Ruiz, Simon Crouch, Alexandra Smith, Daniel J. Hodson, Cathy Burton, Peter J. Campbell, Reuben Tooze, Paul Glover, Sharon Barrans, Daniel Painter, Nichola Webster, Suzan Van Hoppe, Eve Roman, Susanna L. Cooke
Publikováno v:
Blood
Based on the profile of genetic alterations occurring in tumor samples from selected diffuse large B-cell lymphoma (DLBCL) patients, 2 recent whole-exome sequencing studies proposed partially overlapping classification systems. Using clustering techn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50d313e21dee30de844736a9f80d80fa
Autor:
Jan Taylor, Paul Evans, Catherine Cargo, Simon Crouch, Suzan Van Hoppe, Michael Short, Alexandra Smith, Matthew J. Cullen, Paul Glover
The diagnosis of chronic myelomonocytic leukemia (CMML) remains centered on morphology, meaning that the distinction from a reactive monocytosis is challenging. Mutational analysis and immunophenotyping have been proposed as potential tools for diagn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb6584b32fa76f6ee4b02a885782a7c4
https://eprints.whiterose.ac.uk/141367/1/Manuscript_CMML_Blood_submission.pdf
https://eprints.whiterose.ac.uk/141367/1/Manuscript_CMML_Blood_submission.pdf
Autor:
Suzan Van Hoppe, Kikkeri N. Naresh, Jessica Okosun, Michael A. Bentley, Ai Nagano, Jun Wang, Jude Fitzgibbon, Margaret Ashton-Key, Chulin Sha, Andrew Davies, Lisa M. Rimsza, Menon Geetha, Emil Kumar, Findlay Bewicke-Copley, John G. Gribben, Andrew Clear, Daniel Painter, David R. Westhead, Thomas Cummin, Nicola Crosbie, Maria Calaminici, Simon Rule, Mohamed Elshiekh, David Scott, Shamzah Araf, Koorosh Korfi, Cathy Burton, Alexandra Smith, Peter Johnson, S. Barrans
Publikováno v:
Blood. 134:2769-2769
Background: Although diffuse large B cell lymphoma (DLBCL) can be cured using immuno-chemotherapy, 40% of patients experience relapse or refractory disease. Large-scale profiling studies have mainly focused on DLBCL at diagnosis, resolving different